Aktie A14UX2 AMARANTUS BIOSCIENCE HOLDINGS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Amarantus BioScience Holdings, Inc.

Aktien

A14UX2

US02300U2050

AMBS

Verzögert OTC Markets
Andere Börsenplätze
 16:01:04 15.05.2024 		% 5 Tage % 1. Jan.
0,0001 USD 0,00 % Intraday Chart für Amarantus BioScience Holdings, Inc. 0,00 % -80,00 %
2022 Sektor Update: Finanzwerte tragen weiter zu den Rückgängen vom Mittwoch bei MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Sector Update: Financial Stocks Still Adding to Wednesday Declines
Amarantus BioScience : Notification of Late Filing
Amarantus BioScience : Todos Medical Completes Acquisition of Breakthrough Diagnostics, Gains Full Rights to the Alzheimer’s Blood Diagnostic LymPro™ Test from Amarantus
Todos Medical Ltd. (OTCPK:TOMD.F) completed the acquisition of remaining 80.01% stake in Breakthrough Diagnostics Inc. from Amarantus BioScience Holdings, Inc.
Emerald Organic Products : Restructures Joint Venture Agreement With Todos Medical by Entering Joint Collaboration Agreement
Amarantus BioScience : Todos Medical and 3DMed Enter Into Coronavirus (COVID-19) and Influenza A/B Testing Kit Distribution Agreement in US and Israel
Amarantus BioScience : Announces Subsidiary MANF Therapeutics Enters Into Material Transfer Agreement with Dyadic International
Amarantus Releases Letter to Shareholders
Amarantus Acquires Majority Interest in CBD Wellness Company Hempori
Amarantus BioScience Holdings, Inc. acquired majority interest in Hempori, Inc. for $0.38 million.
Emerald Organic Products : Amarantus Completes Sublicense of ESS, MANF and PhenoGuard to Emerald Organic Products
Amarantus Completes Sublicense of ESS, MANF and Phenoguard to Emerald Organic Products
Amarantus to Present at 12th Annual LD Micro Main Event
Amarantus Subsidiary Elto Pharma Receives Notice of Allowance Covering Use of Eltoprazine Combined with CBD to Treat Parkinson’s Disease
Amarantus Announces Issuance of Chinese Patent Covering the Use of MANF and CDNF in Retinal Disorders for Subsidiary MANF Therapeutics
Amarantus Announces Issuance of Chinese Patent Covering the Use of MANF and CDNF in Retinal Disorders for Subsidiary Manf Therapeutics
Amarantus Provides Recapitalization Update to Shareholders
Amarantus Enters Into Agreement to License Diverse Therapeutics Portfolio to CBD-focused Emerald Organic Products
Amarantus Bioscience Holdings, Inc. Enters into Agreement to License Diverse Therapeutics Portfolio to CBD-Focused Emerald Organic Products with Emerald Organic Growth, Inc
Coeptis Pharmaceuticals, Inc. terminated the acquisition of Elto Pharma, Inc. from PsychoGenics Inc. and Amarantus BioScience Holdings, Inc..
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A14UX2 Aktie
  4. Nachrichten Amarantus BioScience Holdings, Inc.
  5. Andere Sprachen